SecBot SecBot
PRESS-RELEASE ·Filed Mar 31, 2026

SCYX

Scynexis
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · M&A
Actionable Insight ▲ Bullish

The acquisition is a strategic pipeline expansion into a rare disease with high unmet need and commercial precedent (Jynarque's $1.5B sales). With a clear development path starting in late 2026 and low upfront cost relative to potential upside, this could re-rate SCYX's valuation if early data is positive. Traders should monitor the Phase 2 initiation in Q4 2026 and watch for enrollment updates as catalysts.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.34
T+0 close · Mar 31, 2026 · via day close
Latest settled
−47.52%
T+60 · $3.85
Vs SPY
−59.90%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 31 $7.34entry
  2. T+1 · 8mo ago −3.16%α −3.92% · $7.10
  3. T+5 · 7mo ago +8.62%α +4.67% · $7.97
  4. T+20 · 7mo ago +1.85%α −7.56% · $7.47
  5. T+60 · 5mo ago −47.52%α −59.90% · $3.85
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Scynexis (SCYX) announced the acquisition of PXL-770 (now SCY-770), a clinical-stage oral therapy for autosomal dominant polycystic kidney disease (ADPKD), from Poxel S.A. The deal includes an $8 million upfront payment, $8 million in potential development milestones, and up to $180 million in commercial milestones. SCY-770, a novel AMPK activator with orphan drug designation, is expected to enter a Phase 2 proof-of-concept study in Q4 2026, positioning Scynexis to expand into a high-unmet-need rare disease market.

Key Financial Metrics

Deal Value
$8.0M

Key Facts

  • Scynexis acquired SCY-770 (formerly PXL-770) from Poxel S.A. for $8M upfront and up to $196M in total milestones ($8M development + $180M commercial).
  • SCY-770 is a novel, oral, direct AMPK activator with orphan drug designation for ADPKD, a rare genetic kidney disease with limited treatment options.
  • Phase 2 proof-of-concept study in ADPKD patients expected to start in Q4 2026, with early efficacy readout in second half of 2027.
  • Current ADPKD market has only one approved therapy (Jynarque), which had ~$1.5B in U.S. sales in 2024 despite limited uptake.
  • Scynexis has potential to receive up to $146M in annual sales milestones and low-to-mid-single-digit royalties from GSK on Brexafemme.

Financial Impact

$8 million upfront cash payment, $8 million in potential development milestones, and up to $180 million in commercial milestones based on sales performance

cashfuture revenueR&D pipeline value

Risk Factors

  • SCY-770 is still pre-clinical for ADPKD; efficacy in this indication is unproven despite prior safety data in NAFLD.
  • Scynexis has limited cash resources; future funding needs could lead to dilution.
  • Milestones are contingent on clinical and commercial success, high risk given early stage.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3265277

Track record

14 reports on SCYX

Performance horizon

4 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +33.49% at T+20 after the May 11, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $2.91 Now $2.91 +0.00% settles Nov 24
  2. Nov 5, 202611d ago S-3 Neutral 3/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  3. Nov 5, 202611d ago Press Release Neutral 4/10 Entry $3.30 to $3.33 Now $2.91 −11.82% ▲ +0.91% −2.38% vs SPY
  4. Oct 22, 202625d ago Press Release Bullish 7/10 Entry $3.81 to $3.86 Now $2.91 −23.62% ▲ +1.31% +0.61% vs SPY
  5. Oct 6, 20265w ago Press Release Neutral 4/10 Entry $4.84 to $3.99 Now $2.91 −39.88% ▼ −17.56% −17.42% vs SPY
  6. Sep 28, 20267w ago Press Release Bullish 6/10 Entry $4.62 to $5.03 Now $2.91 −37.01% ▲ +8.87% +7.67% vs SPY
  7. Sep 22, 20267w ago 8-K Neutral 2/10 Entry $4.86 to $4.66 Now $2.91 −40.12% ▼ −4.12% −2.93% vs SPY
  8. Sep 10, 20269w ago 8-K Neutral 2/10 Entry $4.70 to $4.45 Now $2.91 −38.09% ▼ −5.32% −4.82% vs SPY
  9. Jun 26, 202620w ago 8-K Neutral 3/10 Entry $3.87 to $4.73 Now $2.91 −24.81% ▲ +22.22% +20.83% vs SPY
  10. May 22, 202625w ago 8-K Neutral 4/10 Entry $5.45 to $5.33 Now $2.91 −46.59% ▼ −2.17% −3.25% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 6h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 31, 2026